Aankondiging • Jun 24
Immupharma Reports University of Murcia Research on P140 Peptide in Glioblastoma Immupharma plc noted the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University of Murcia relating to the P140 peptide and its potential application in glioblastoma, an aggressive form of brain cancer. Immupharma acknowledged the quality of the scientific work conducted by the University of Murcia in this area and confirmed that it has been aware of, and has followed, this research since 2024 and is in regular contact with the research team at the University of Murcia. These findings are supportive of Immupharma's broader scientific work on P140 and are consistent with the scientific rationale underlying the program. P140 remains Immupharma's lead asset, and the company's primary focus continues to be the advancement of P140 in autoimmune disease. Further updates will be provided to the market when appropriate. Aankondiging • Jun 03
ImmuPharma plc, Annual General Meeting, Jun 25, 2026 ImmuPharma plc, Annual General Meeting, Jun 25, 2026. Location: the offices of broadfield law uk llp, one bartholomew close, london ec1a 7bl United Kingdom Aankondiging • May 06
ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat Diabetes ImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon. New Risk • Apr 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£29.0m market cap, or US$38.9m). Aankondiging • Mar 28
ImmuPharma PLC Provides Update on P140 Program Patent Progress and Supporting Data ImmuPharma PLC had received a first Combined Search and Examination Report in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The results were positive and supportive of the patent application. The scientific team is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community. P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value-enhancing licensing deal in 2026. ImmuPharma will provide further updates on the P140 program as appropriate. Aankondiging • Mar 23
ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million. ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,812,447
Price\Range: £0.06 Aankondiging • Mar 17
ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million. ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 100,000,000
Price\Range: £0.06 New Risk • Feb 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£42.7m market cap, or US$57.6m). Aankondiging • Oct 13
ImmuPharma plc Announces Appointment of Ketan Patel as an Independent Non-Executive Director, effective October 13, 2025 ImmuPharma plc announced the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect October 13, 2025. Ketanis an experienced investment professionaland brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategiesdelivering consistent upper quartile performance. Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes, Ketan is a CFA Charterholder. He also holds anMSc Economic History, fromLondon School of Economics, MSc Geography from King's College London and BA (Hons) History and Geography from Queen Mary University, London. Board Change • Sep 08
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Aug 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£8.43m market cap, or US$11.3m). Aankondiging • May 20
ImmuPharma plc, Annual General Meeting, Jun 12, 2025 ImmuPharma plc, Annual General Meeting, Jun 12, 2025. Location: the malmaison hotel, 18 21 charterhouse square, barbican, ec1m 6ah, london United Kingdom New Risk • May 19
New major risk - Negative shareholders equity The company has negative equity. Total equity: -UK£543k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-UK£543k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£15.0m market cap, or US$20.0m). New Risk • Apr 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£18.5m market cap, or US$24.6m). New Risk • Mar 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.7m market cap, or US$16.5m). Aankondiging • Feb 21
ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million. ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,586,667
Price\Range: £0.0375
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: £0.0375
Transaction Features: Subsequent Direct Listing Aankondiging • Feb 14
ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million. ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,586,667
Price\Range: £0.0375
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: £0.0375
Transaction Features: Subsequent Direct Listing Aankondiging • Jan 09
ImmuPharma plc Announces Breakthrough Findings into Autoimmune Diseases ImmuPharma PLC announced innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Importantly for autoimmune therapy P140, especially for lead indication in SLE, these findings pave the way for: Earlier and more accurate diagnostics; Identifying patients most likely to respond to P140 therapy; and Improved monitoring of the patient's response to treatment with P140. Through this research, the company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. The Company is not at this time releasing detailed data as these findings form part of the ongoing expansion of intellectual property portfolio including additional patents for P140. New Risk • Jan 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.6m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£5.23m market cap, or US$6.53m). Aankondiging • Dec 04
Immupharma plc Announces Appointment of Ashley Clarke as Company Secretary ImmuPharma plc to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect. Ashley has been closely involved with the Company's accounts for several years via outsourced accountants, providing her with deep familiarity with ImmuPharma's operations. Now, as Group CFO, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure continued robust fiscal management. (More details on Ashley in 'Notes to Editors'). Aankondiging • Sep 17
Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical Conference Immunovia presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test's performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of 85% and specificity of 98%, as reported in a 1 August 2024 press release. The sensitivity of the Immunovia test exceeded that of CA19-9, a commonly used biomarker for pancreatic cancer, by 20 percentage points. The conference is being hosted by the American Association for Cancer Research (AACR) in Boston, Massachusetts. This special conference brings together leading pancreatic cancer researchers, physicians, and patient advocates to share innovative approaches for diagnosing and treating pancreatic cancer. Aankondiging • Jul 29
ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024 ImmuPharma plc announced that they will report Q2, 2024 results at 8:30 AM, Central European Standard Time on Aug 05, 2024 Aankondiging • Jun 08
ImmuPharma plc, Annual General Meeting, Jun 28, 2024 ImmuPharma plc, Annual General Meeting, Jun 28, 2024. Location: the offices of evelyn partners, 45 gresham street, ec2v 7bg, london United Kingdom Aankondiging • Apr 30
Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director Immunovia announced the appointment of Dr. Lisa Fordas Clinical Laboratory Director. As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners, especially Proteomedix. Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests. She has extensive experience overseeing clinical and bioanalytical laboratories and associated quality systems, managing clinical assay development, validation projects, quality improvement and laboratory personnel. Lisa holds a Ph.D. from Duke University in Bioorganic Chemistry and a B.S. from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis. New Risk • Mar 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (UK£70k revenue, or US$89k). Market cap is less than US$10m (UK£7.72m market cap, or US$9.84m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Aankondiging • Dec 19
Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm ImmuPharma PLC announced key updates on its late stage P140 (Lupuzortm) program, in patients with systemic lupus erythematosus ("SLE/Lupus"). The design of the pivotal Phase 3 study includes a dose-range. This design is faster to complete than a Phase 2/3 adaptive study, while at the same time incorporating all the key objectives. The company confidently expect the efficacious dose to be within this dose-range and The company expects no adverse events that could lead to product label warnings seen with all other approved drugs and standard of care, which are all immunosuppressants. The study design allows two interim analyses, so there will be short term updates on clinical activity of the drug. P140 is not an immunosuppressant, so a key objective will be to taper the use of steroids which are currently standard of care. This distinction sets the stage for a new gold standard therapy, conveniently self-administered by the patient, once a month, which is safe and well tolerated unlike standard of care or any other molecule in development which are all immunosuppressedants with significant safety warnings. Further details on the protocol and key elements of the clinical trial design will be communicated, once the details of the trial are available on clinicaltrials.gov (a comprehensive database of privately and publicly funded clinical studies conducted around the world). The international Phase 3 dose-ranging study design and protocol is substantially different from previous clinical trials completed by ImmuPharma. Dosing will still be a subcutaneous injection, once a month, but with significantly higher doses, which have demonstrated safety and tolerability as part of the clinical program. Two planned interim analyses during the course of the study will allow early indications of the effectiveness of P140. Recent further insights into P140's mechanism of action supports its position as the only non-immunosuppressing molecule in clinical development in the industry. A new potential standard of care for SLE sufferers. As the study continues to move forward in 2024, further details on the study's timings, protocol and key elements of theclinical trial design will be communicated at regular intervals. Simbec-Orion, is an experienced, full-service Contract Research Organisation, with offices across UK, Europe, and the United States, specialising in Rare & Orphan conditions. Simbec-Orion has previous direct experience in Lupus trials including conducting ImmuPharma's last Phase 3 study completed in 2018 and more recently conducted ImmuPharma's Pharmacokinetics (" PK") study completed in 2022. The whole P140 program was re-examined in 2021, and the Board decided that it required a completely different approach, not only to commence a new Phase 3 study in Lupus, but also to be clear on the product offering and target product profile. The three pillars of strength and confidence in new program are dose, design and MOA. Dose After three FDA guidance meetings, further human and animal pharmacokinetics studies and reconciliation with efficacy demonstrated in the animal models, it was concluded that the previous dose used in clinical studies was too low. The new Phase 3 study will include dose-ranging up to 15 times higher than the original study dose of 200 micrograms. Design The design of the pivotal Phase3 study includes a dose- range. This design is faster to completed than a Phase 2/3 Adapted study, while at the sametime incorporating all the key objectives. Aankondiging • Nov 09
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development Immunovia announced the successful completion of the discovery phase for the Company's next-generation test. The discovery study, which marks a key milestone in the development of Immunovia's next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic proteomics study done to date and utilized the Olink platform to explore nearly 3,000 protein biomarkers. The new test is designed to work across all racial and ethnic groups without compromising accuracy, overcoming a key limitation of Immunovia's first-generation test, IMMray PanCan-d. Immunovia and its development partner Proteomedix are in the process of developing high- quality assays to accurately measure the identified biomarkers. The next step will be to complete a study to select which biomarkers to include in the commercial test, optimize the test, and assess its accuracy. Later in 2024, Immunovia will confirm the analytical validity of the test and conduct a large clinical validation study. Board Change • Oct 12
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. 6 highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Cees Kallenberg is the most experienced director on the board, commencing their role in 2013. Senior independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Aankondiging • Aug 12
ImmuPharma plc Announces Changes to Its Board of Directors ImmuPharma plc announced the appointment of Dr. Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr. Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience. He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry. Through his consulting practice (Acumen Life Science Investment Consulting) .Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr. Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously served as a Clinician - Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor. Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K. The company also extremely welcomed DrSébastien Goudreau to the Board. Dr Goudreau joined ImmuPharma in 2014 as research director and established the research laboratories of Ureka Pharma (now ImmuPharma Biotech, the Company's French subsidiary) in Bordeaux, being promoted in 2021 to Chief Executive Officer of ImmuPharma Biotech. Notably, working directly with Dr Tim Franklin (ImmuPharma COO), Dr Goudreau and his team are credited for the development of, among others, the Company's anti-infective programmes, BioAMBand BioCin. Dr Goudreau has also been a key contributor to the progression of the P140 autoimmune platform including the PK study, successfully concluded in 2022, and supported the new protocol design of the Phase 2/3 adaptive clinical studies for both Lupus and CIDP. Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. At this time, Dr Sanjeev Pandya, has informed the Board that he wishes to step down from his Non-Executive Director position, in order to pursue a number of other external opportunities. All Board changes take place with immediate effect. Aankondiging • Jul 13
Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer Detection Immunovia announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the Company's promising next generation pancreatic cancer detection test. The next generation assay currently in development is intended to work equally well across multiple patient risk groups. The new test is expected to provide accurate results in patients who do not produce CA19-9, and to reduce reliance on CA19-9, which have been limitations of IMMray PanCan-d. The next generation test will be performed on a widely used commercial platform, enabling the company to better scale production. Immunovia expects to release further details about the next-generation test later this year, with an anticipated launch date in 2024. Immunovia's strategic decision to focus on its next generation assay will result in significant layoffs in both Sweden and the United States in multiple functions. Importantly, the staffing reductions and the elimination of other operating expenses will lower the company's cash burn rate and extend the Company's cash reserves well into 2024. New Risk • Jun 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.82m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.82m market cap, or US$9.94m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Aankondiging • Jun 06
ImmuPharma plc, Annual General Meeting, Jun 30, 2023 ImmuPharma plc, Annual General Meeting, Jun 30, 2023, at 10:00 Coordinated Universal Time. Location: One Bartholomew Close London, EC1A 7BL London United Kingdom Aankondiging • May 23
ImmuPharma plc, Annual General Meeting, May 26, 2023 ImmuPharma plc, Annual General Meeting, May 26, 2023, at 09:00 Central European Standard Time. Location: The Spark, Scheeletorget 1, Medicon Village, Lund. Lund Sweden Aankondiging • Jan 20
Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d test Immunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. In October 2022, Immunovia announced a research collaboration partnership with Proteomedix. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics. Following the early experience of the collaboration Immunovia has been able to better understand the opportunities available to the company and has determined that the in-house need for R&D capability has changed. As a result, Immunovia has initiated a union consultation process with the aim of reducing the number of employees within R&D and Operations in Lund. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees. The Company will provide an update once the consultation process is concluded. Aankondiging • Jan 18
Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market Immunovia announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023. Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics. Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University. Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis. Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications. Her academic research was funded by the National Institutes of Health and Department of Defense. She has extensive experience in leading clinical science teams and collaborating with key opinion leaders. Lara holds a PhD in Genetic and Molecular Epidemiology from Case Western Reserve University, an MS in Genetic Counseling from The Ohio State University as well as degrees in engineering and economics. Price Target Changed • Nov 16
Price target decreased to UK£0.029 Down from UK£0.036, the current price target is provided by 1 analyst. New target price is 16% above last closing price of UK£0.025. Stock is down 63% over the past year. The company posted a net loss per share of UK£0.033 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior Independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 30
First half 2022 earnings released: UK£0.006 loss per share (vs UK£0.015 loss in 1H 2021) First half 2022 results: UK£0.006 loss per share (improved from UK£0.015 loss in 1H 2021). Net loss: UK£1.66m (loss narrowed 55% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Reported Earnings • May 26
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: UK£0.032 loss per share. Net loss: UK£8.17m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 12%. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 03
First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020) First half 2021 results: Net loss: UK£3.66m (loss widened 24% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Board Change • Aug 10
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Executive Departure • Aug 05
Independent Non-Executive Director Stéphane Robert Méry has left the company On the 30th of July, Stéphane Robert Méry's tenure as Independent Non-Executive Director ended after 6.3 years in the role. As of March 2021, Stéphane Robert still personally held only 21.49k shares (UK£1.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Aug 05
Senior Independent Non-Executive Director Franco Di Muzio has left the company On the 30th of July, Franco Di Muzio's tenure as Senior Independent Non-Executive Director ended. As of March 2021, Franco still personally held only 99.41k shares (UK£8.8k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 02
Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the company On the 28th of June, D. Henri Zimmer's tenure as Co-Founder, President, Chief Scientific Officer & Director ended after 15.4 years in the role. As of March 2021, Henri Zimmer still personally held 27.34m shares (UK£2.4m worth at the time). Henri Zimmer is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.33 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • May 01
Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019) Full year 2020 results: Net loss: UK£6.86m (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 03
First half earnings released Over the last 12 months the company has reported total losses of UK£5.18m, with losses narrowing by 26% from the prior year.